RhumbLine Advisers’s Palisade Bio PALI Stock Holding History
Bought
Maintained
Sold
Other funds holding PALI
BGI
RhumbLine Advisers's PALI Position: Q3 2026 in Review
RhumbLine Advisers increased its Palisade Bio (PALI) stake by 7.3% in Q3 2026, buying an estimated $22.8K and bringing the position to 172,442 shares worth $233K. The position accounts for ﹤0.01% of the portfolio, ranked #3192.
RhumbLine Advisers first reported a position in PALI in Q2 2026 and has held it in 2 quarters since. The position peaked at $336K in Q2 2026. 114 funds tracked by Wall St. Rank hold PALI as of Q3 2026.
- RhumbLine Advisers held 172,442 shares of Palisade Bio worth $233K as of Q3 2026.
- RhumbLine Advisers bought 11,669 Palisade Bio shares in Q3 2026, an estimated $22.8K.
- Palisade Bio made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #3192 holding.
- RhumbLine Advisers first reported a position in Palisade Bio in Q2 2026 and has held it in 2 quarters since.
- RhumbLine Advisers's Palisade Bio position peaked at $336K in Q2 2026.
- 114 funds tracked by Wall St. Rank held Palisade Bio as of Q3 2026.
Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.